The U.S. health regulator ordered painkiller makers to provide educational materials to help train physicians about the correct use of the drugs, as part of the Obama administration’s plan to tackle prescription drug abuse. Get the full story »
Filed under: Pharmaceuticals
Baxter International Inc. said it will pay at least $170 million to buy a specialty drug maker that has high hopes for a heart drug used in hospitals to treat irregular heart beats. Get the full story »
Pfizer Inc. said on Friday its experimental rheumatoid arthritis drug met most of the main goals of a late-stage clinical trial.
If approved, it would compete with injectable treatments such as Humira, made by Abbott Laboratories, Amgen Inc.’s Enbrel, and Remicade, made by Johnson & Johnson. Get the full story »
Drugstore.com rejected a pair of lower offers from Walgreen Co. during a yearlong courtship before accepting a third proposal worth about $429 million, the Bellevue, Wash.-based Internet retailer disclosed in a regulatory filing Wednesday.
Drugstore.com agreed March 23 to be bought by Walgreens, the nation’s largest drugstore chain, for $3.80 a share in cash, a 111 percent premium over the stock’s closing price a week earlier. The planned purchase, which is subject to approval by drugstore.com shareholders, is expected to be final by the end of June. Get the full story »
From Bloomberg News | Abbott Laboratories’ Humira spurred resistance in more than a quarter of patients taking the rheumatoid arthritis drug in a study, a finding that may weaken demand for the company’s top-selling medicine. Get the full story>>
Endo Pharmaceuticals Holdings Inc. said Monday it is buying urology and pelvic health company American Medical Systems Inc. for about $2.6 billion. Get the full story »
Johnson & Johnson has agreed to pay $70 million to settle U.S. charges that it paid bribes and kickbacks to win business overseas, the first major pharmaceutical company to settle since the Obama administration began its scrutiny of the industry more than a year ago. Get the full story »
Merck & Co. said Tuesday that it would acquire eye treatment maker Inspire Pharmaceuticals Inc. for about $430 million to expand its ophthalmology business. Get the full story »
Walgreen Co. said today its March sales rose 7.6 percent in March, helped in part by its acquisition last year of New York pharmacy chain Duane Reade. Get the full story »
Abbott Laboratories’ experimental device to repair leaky heart valves continues to show promise in patients two years after they have been treated, new research published in the New England Journal of Medicine today shows.
The MitraClip device, which is currently being review by the U.S. Food and Drug Administration for possible approval, is considered an important development for heart patients with mitral regurgitation because serious cases require open-heart surgery to repair their valves. It could be on the U.S. market by the end of this year. Get the full story »
Abbott Laboratories Inc.’s experimental Absorb heart stent, designed to dissolve and thereby restore the blood vessel’s natural flexibility, has proven safe and effective a year after being implanted in patients, researchers said. Get the full story »
From Bloomberg News | A federal jury has ordered Abbott Laboratories to pay drug giant GlaxoSmithKline $3.5 million in damages in an antitrust lawsuit claiming Abbott sought to stifle competition over HIV drugs when it quadrupled the price of its AIDS medicine Norvir in 2003.
A U.S. Food and Drug Administration chemist and his son were charged with using inside information about drug approvals to reap more than $3.6 million in profits, in an embarrassing blow to the health industry regulator. Get the full story »
Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed. Get the full story »
Abbott Laboratories said Tuesday that it received marketing approval for a version of its i-STAT 1 blood testing system that can transmit results wirelessly. Get the full story »